BACKGROUND: Traditional education about hemophilia B in hemophilia treatment centers (HTCs) and episodic contact with HTCs limit the amount of education patients and their caregivers receive. Specialty care providers have frequent, continuing contact with patients. Each contact with a specialty care provider (e.g., coordinating a refill or addressing a patient inquiry) is another opportunity to support patient self-management of the disease and to give counsel on appropriate medication administration. The role of specialty pharmacy in improving patient self-management and supporting medication management and adherence is well established and reported with rheumatoid arthritis, multiple sclerosis, and renal transplant. With hemophilia, specialty pharmacies can support educational reinforcement of HTCs as well as support patient self-management and education of medication therapy. Utilization of patient education materials and programs can facilitate such a role. BE EMPOWERED, a specialty pharmacy education program for hemophilia B patients, is a multimodule education program coupled with frequent telephonic outreach.
H emophilia comprises 2 distinct inherited X-linked disorders that result in prolonged bleeding. Hemophilia A is a deficiency of functional clotting factor VIII, while hemophilia B is a deficiency of clotting factor IX. Hemophilia B occurs in approximately 1 in 10,000 male births, comprising 15% to 20% of cases of all races and economic groups. 1 Both hemophilia A and B are classified as mild, moderate, or severe based on the individual's factor activity, and those with either disorder have similar bleeding tendencies. People with severe hemophilia (< 1% of normal clotting factor activity) often experience spontaneous bleeds into joints and muscles. People with moderate hemophilia (1%-5% of normal clotting factor activity) occasionally experience spontaneous bleeding but more often have prolonged bleeding after minor insults, while those with mild hemophilia (5%-40% of normal activity) rarely bleed and usually experience bleeding only in response to severe trauma or surgery. Repeated bleeding into joints and muscles often leads to progressive deterioration and long-term disability. Because treatment consists of intravenous infusions of the missing clotting factor, extensive patient and family education is required to help prevent long-term complications.
R E S E A R C H
• Educational programs are often delivered by health care professionals during hemophilia treatment center visits.
• Adequate management of factor therapy entails knowledge assessment, tailored educational interventions, and behavior modification techniques.
• Some approaches have sought to establish patients with hemophilia as educators ("patient tutors") who help educate their peers through an interactive framework.
What is already known about this subject
• Customized programs that reinforce adherence to appropriate hemophilia management may have beneficial results on multiple hemophilia outcomes.
• Completing the BE EMPOWERED program was associated with a decrease in total and joint bleeds in adults and with increased RICE utilization in children, as reported by caregivers.
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clinicians familiar with hemophilia B and the barriers faced in therapy regimen adherence. Each module had a specific educational focus, and a summary of each module is provided in Table 1 . All materials and the informed consent document were reviewed and approved by the Western Institutional Review Board, as well as relevant Accredo and Pfizer committees.
Patients were eligible for inclusion if they were male hemophilia B patients receiving recombinant factor IX (nonacog alfa; BeneFIX, Pfizer Inc, Philadelphia, PA) through Accredo's Hemophilia Health Services for 12 months prior to study participation (between June 1, 2009, and May 30, 2010); were caregivers of patients with hemophilia B aged 4 to 17 years; or were adults aged 18 years or older with hemophilia B who had received nonacog alfa from Accredo for 12 months prior to participation. Patients were excluded if they were female, were affiliated with a client of Accredo who had opted out of any type of mail education information materials, or resided in Florida.
Informed consent was obtained by the study nurse coordinator, who also recorded baseline information during the telephonic interactions. Nonacog alfa was selected as the factor to evaluate during this program because at the time it was the only recombinant factor IX currently on the market and has the highest utilization among hemophilia B patients. In all, 438 hemophilia B patients were identified and invited to participate in the BE EMPOWERED program, and 179 volunteered to participate. Their participation involved completion of the educational modules and completion of a voluntary baseline and follow-up survey.
Comprehensive care for people with hemophilia B involves ongoing education and reinforcement of adherence to prescribed factor therapy, including bleeding episode management. Educational programs are often delivered by health care professionals during hemophilia treatment center (HTC) visits. The HTCs comprehensively approach the case of the patient and the patient's family by attempting to address the ongoing medical, physical therapy, and psychosocial aspects of hemophilia, which can include educational and emotional support. The HTC is the primary point of education, with goals to deepen the patient's and family members' understanding of the disease and to facilitate development of independence in leading a full life. A multimodule approach that includes patient outreach when a patient or family is not at their HTC provides an additional opportunity to support the educational activities of the HTC toward appropriate factor therapy and bleeding management. Specialty pharmacy providers are well positioned to deliver educational programs that reinforce physician-prescribed hemophilia care management.
Adequate management of factor therapy entails knowledge assessment, tailored educational interventions, and behavior modification techniques provided by specialist pharmacists and nurses. Historically, the medical literature has not included evaluation of specialty pharmacy providers as a mode of delivering this information to hemophilia patients. Some approaches have sought to establish patients with hemophilia as educators ("patient tutors") who help educate their peers through an interactive framework. 2 Other interventions have included informal self-learning programs on the Internet. 3, 4 However, additional programs supporting enhanced knowledge and self-management skills are needed.
Customized programs that reinforce adherence to appropriate hemophilia management may have beneficial results on multiple hemophilia outcomes. Examples of such outcomes include joint bleeds, emergency department visits, hospitalizations, surgeries, enhanced adherence to a prescribed drug regimen, and healthy lifestyle. 5 Although not an educational intervention, the Joint Outcome Study 5 found that adherence to therapy improved joint health and function. The BE EMPOWERED program, a specialty pharmacy education program for hemophilia B patients, provided an educational experience based upon discrete curriculum modules that were facilitated by a specialty pharmacy-based nurse educator. The results of this proof-of-concept, structured educational program are reported here.
■■ Methods
The BE EMPOWERED educational program, jointly developed by Accredo Health Group and Pfizer, Inc., was based on the Health Belief Model, which assumes healthy behaviors will increase with a better understanding of a patient's disease state and treatment. 6 Educational modules were developed by 
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A welcome packet sent out to eligible patients included a baseline survey and a treatment journal with a postage prepaid envelope for returning completed surveys. See Table 2 for details of the baseline and follow-up surveys. Three BE EMPOWERED educational pamphlets were mailed 1 month apart, with follow-up counseling telephone calls approximately 1 week after each module to discuss the content. The study nurse coordinator followed a structured format for reviewing module topics with each patient, ensuring consistency between patients. The calls were approximately 15 to 20 minutes in duration, which allowed time to address patient questions on the modules in addition to allowing the nurse educator to highlight key hemophilia management concepts and address medication adherence. Subsequent to the third module call, a follow-up voluntary survey was mailed with a postage prepaid envelope for returning completed surveys. The total study period was approximately 6 months, which included 1 month of enrollment, 3 months of educational intervention, and 2 months for return of surveys for data collection.
Data collected included the baseline and follow-up surveys; prescription refill data and infusion logs; self-reported (or caregiver-reported) adherence to regimen prescribed by the patient's physician; self-reported (or caregiver-reported) bleeding events; factor usage (prescription refill history); school participation (absenteeism, arriving late, leaving early, visiting the school nurse); social and physical activities; and use of RICE (rest, ice, compression, and elevation) for adjunctive therapy for addressing bleeds. RICE is part of the recommended comprehensive approach to treating bleeding events and is included in the guidelines for the management of hemophilia. 7 Quality of life (QoL) was assessed at the beginning of the study in the baseline survey and at the end of the program in the follow-up survey. The hemophilia-specific QoL tool (HAEMO-QoL-A) was used for adults because this tool has demonstrated excellent internal consistency, high reliability, and construct validity. 8 The validated caregiver short version of the Hemophilia QoL Questionnaire for Children (HAEMOQoL) was utilized, with one version for caregivers of children aged 4 to 7 years and another version for caregivers of children aged 8 to 16 years. An overall QoL score was calculated from raw item scores, which were translated into transformed scale scores (TSS) ranging from 0 (highest QoL) to 100 (poorest QoL). 8 Quantitative assessment of adherence to nonacog alfa was based on modification of the medication possession ratio (MPR). The MPR is a standard measure using pharmacydispensing data to determine if patients have enough medication on hand to be adherent to their prescribed regimens. The MPR is the sum of the days' supply of medicine divided by the number of days between the first fill and last refill plus the days' supply of the last refill. This results in a ratio that is less than 1 when patients are nonadherent to the prescribed regimen. Early refills result in an MPR that is greater than 1. One or 100% is often the maximum value, since it has the potential Description of Patient Self-reported Survey Administered at Baseline and Follow-up Ability to identify, treat, and reduce the risk for developing a bleed (self-rated on a 5-point scale from "not at all able" to "highly able") Belief that various symptoms were related to a bleed (i.e., warm tingling feeling in joint, pain, stiffness, swelling, redness, difficulty moving, irritability, drowsiness, headache; self-rated on a 5-point scale from "not related to a bleed" to "highly related to a bleed") General treatment of a bleed In the past 6 months, how many times have you missed a doctor-recommended or scheduled infusion? In the past 6 months, how many times did you not recognize that you were experiencing a bleed? In the past 6 months, how many times was a bleed untreated because you were away from your medication or in an inconvenient location to infuse? What are the top 3 concerns in following the treatment plan prescribed by your doctor? Likelihood of infusing as prescribed, carrying factor with you when going out, infusing factor as soon as symptoms are noted, seeking assistance in event of a bleed, and use of RICE (5-point scale from "not at all likely" to "extremely likely") Assessment of patient's daily routine (record all bleeds, follow a healthy lifestyle, maintain a healthy weight, regularly exercise; 5-point scale from "not at all likely" to "extremely likely") Impact of hemophilia on quality of life b Impact of hemophilia on work or school, family, and social life Patient experience with hemophilia treatment (i.e., interference with daily activities, stress, safety, availability of hemophilia product) Work productivity (for employed patients) Frequency of engaging in the following activities: (a) swimming, golfing, hiking, walking, or low-impact martial arts such as tai chi; (b) biking, using exercise machine, or weight lifting; (c) bowling, dancing, roller skating, running/jogging, tennis; (d) baseball, basketball, gymnastics, in-line skating, skateboarding, soccer, surfing, or high-impact martial arts such as karate; (e) football, motorcycling, wrestling, hockey, lacrosse, or weightlifting (power lifting for perfect adherence. 9 The MPR metric as defined here is only applicable to medication regimens that have regularly scheduled doses.
Nonacog alfa dosing is variable when used to control or prevent bleeds and is based on several considerations, including severity of factor IX deficiency, individual patient pharmacokinetics, age, and the severity and location of bleeds. In general, 1 international unit (IU) of factor IX increases the plasma level by 1%. Dosing for minor bleeds is in the range of 20 to 30 IU per kilogram (IU/kg) given intravenously every 12 to 24 hours for 1 to 2 days, while the dose for major bleeds is in the range of 50 to 100 IU/kg intravenously every 12 to 24 hours for 7 to 10 days. 10 Because nonacog alfa does not follow a regularly dosing schedule, an adjusted MPR was developed due to the episodic nature of factor infusion that incorporated patientor caregiver-reported information, specifically the number of doses of factor used to treat bleeds.
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Patient-or caregiver-reported persistence to prescribed treatment of bleeds with prompt factor infusion and utilization of adjunctive therapies, such as RICE, was defined as excellent (76%-100% of bleeds), good (51%-75% of bleeds), fair (26%-50% of bleeds), or poor (0%-25% of bleeds). 12, 13 This assessment was done at baseline and at follow-up. Patients were considered to be adherent if their MPRs were ≥ 1, or "persistence" to prescribed treatment was categorized as excellent.
All categorical variables were compared using the chisquare test and continuous variables using the independent samples t-test, with P ≤ 0.05 indicating significance. Survey responses between adherent and poorly adherent patients were examined in relation to QoL. In particular, differences between HAEMO-QoL-A scores were explored between the adherent and nonadherent patients (using t-tests). Statistical analyses were performed using SAS version 9.3 (SAS Institute, Inc., Carey, NC).
■■ Results
Of 438 patients identified receiving nonacog alfa, 179 (41%) patients or caregivers met the inclusion criteria and The majority of participants completing the study were white and included 71% of caregiver and 94% of adult participants. The mean ages of caregivers and adults with hemophilia B completing the study were similar, at 43 and 44 years, respectively ( Table 3 ). The mean age of children receiving nonacog therapy was 10 years. Many of the caregivers completing the study had high education levels (48% associate's or bachelor's degrees), while most adults completing the study had some college education but no degree (47%).
Caregivers were split between on-demand and regular therapeutic regimens (48% vs. 52%, respectively), while adults were more commonly using on-demand treatment compared with children (94% vs. 6%, respectively). Most of caregivers' children had either moderate or severe hemophilia B (62%), and the majority of adults with hemophilia B had either moderate or severe disease (88%).
The BE EMPOWERED educational intervention was scored on a 5-point scale, with 1 being extremely unlikely and 5 being extremely likely for patients to engage in the activity. Responses indicated that BE EMPOWERED had a statistically significant impact on the use of RICE by caregivers, the utilization of which in children rose from 17 (81%) to 21 (95%), as listed in Table 4 . There was little change in adults with hemophilia, who may have already been familiar with this approach. Both before and after the BE EMPOWERED program, most caregivers were likely to infuse as soon as symptoms were noted (81% at baseline; 95% at follow-up), while fewer adults were likely to infuse as soon as symptoms were noted (70% at baseline; 76% at follow-up; P = not significant). With regard to seeking assistance when a bleeding event occurred, caregivers were more likely to seek assistance (71% at baseline; 67% at follow-up) than were adults (41% at baseline; 24% at follow-up). No statistical difference was noted in seeking assistance based on the BE EMPOWERED intervention for either caregivers or adults.
The BE EMPOWERED program did not impact the recognition of pain, stiffness, redness, difficulty moving, or sensation of a pulled muscle as signs of a bleed for either caregivers or adults with hemophilia. However, caregivers reported more improvement in joint bleed recognition through warmth/tingling (71% at baseline; 95% at follow-up) compared with adults (94% at baseline; 94% at follow-up; P ≤ 0.02). Recognition of swelling as a symptom of a joint bleeding event improved among caregivers (81% at baseline; 100% at follow-up; P < 0.05) but not adults (94% before and 94% at follow-up). This suggests a positive correlation with educational intervention for the caregiver group. 
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for enhanced education and patient counseling efforts. It is encouraging to document that this pilot project positively impacted clinical outcomes (e.g., lower ABR for total bleeds and joint bleeds in adults). This may pave the way for expansion of such efforts in the future, using specialty pharmacies as key participants in the care team, providing patient education, and potentially improving clinical outcomes.
One of the more striking outcomes noted from this pilot evaluation centers around the statistically significant drop in both the total number of bleeds in adults (4.7 at baseline; 2.6 at follow-up ) and joint bleeds (3.5 at baseline; 1.7 at followup; P ≤ 0.02). This may indicate that young patients and their caregivers, being relatively new to dealing with hemophilia, have a higher level of understanding of the disease and the importance of treatment. The authors surmise that adults may have forgotten some of the specifics and may have been more distracted by the challenges and responsibilities of adult life. It could also be that caregivers were more vigilant in taking care of their children's hemophilia than adult patients would be in taking care of themselves. It is encouraging that refocusing their attention to the fundamentals of hemophilia in an educational program such as BE EMPOWERED results in memory refreshment that translates into statistically significant and clinically meaningful lower bleed rates.
Adult baseline Haemo-QoL TSS of 67 and 76 in this evaluation were substantially higher than those previously reported by Mercan et al. (2010) , 13 indicating more impairment among U.S. adults than Turkish adults, although there are no specific norms for U.S. versus Turkish patients. Pediatric TSS in this study (21-23 in ages 4-7; 21-30 in ages 8-17) were comparable with those in European reports by Gringeri et al. (2004 14 ;
Among adults, the annualized bleeding rate (ABR) for total bleeds went from 4.7 to 2.5 and, for joint bleeds, improved from 3.5 to 1.7 (P ≤ 0.02) but did not improve among caregiver responses, wherein they were less common overall, with an ABR of 1.1 to 1.2 (Table 4 ; Figures 2 and 3) .
When baseline HEAMO-QoL scores were compared between adherent and nonadherent patients, no statistically significant differences were found between adherent (TSS 76 ± 13) and nonadherent (TSS 67 ± 18) adults. The TSSs in children aged 4 to 7 years (adherent, TSS 30; nonadherent, TSS 41; P = 0.83) and those aged 8-17 (adherent, TSS 23; nonadherent, TSS 21; P = 0.62) were lower than those of adults; indicating overall higher QoL scores in the pediatric group (Table 5) .
When comparing baseline and follow-up HAEMO-QoL scores, no statistically significant changes were noted. Adults maintained high scores (78 at baseline; 76 at follow-up; P = 0.35). Both pediatric groups maintained similar, nonsignificant HAEMO-Qol scores from baseline to follow-up: 22 at baseline and 23 at follow-up (P = 0.97) for ages 4 through 7 and 23 at baseline and 23 at follow-up for ages 8 through 17.
■■ Discussion
Education about hemophilia classically occurs in the HTC setting. Social media (e.g., the Internet) and national organizations also offer educational information. This is the first report of the use of specialty pharmacy as a source of education to complement these existing resources. In contrast to HTCs, wherein contact with the patient is often episodic (e.g., annual visit), specialty pharmacies have multiple and continuing interactions with patients and caregivers throughout the year. Therefore, this existing infrastructure offers an opportunity 
Limitations
These findings should be considered in light of some study limitations. These limitations include the small number of patients completing the pilot program. No effort was made to assess baseline knowledge and to tailor the educational program to meet identified deficits so the BE EMPOWERED modules may not have had a substantial impact, since it may have included material with which the participants were already familiar.
We also found that many of the caregivers completing the study had high education levels (48% associate's or bachelor's degrees), while most adults completing the study had some college education but no degree (47%). Due to the small number of patients in the program and study evaluation, the authors were not able to stratify the data to assess the potential effect that baseline education may have had on the comprehension of the pamphlets. Future studies should attempt to take this into consideration.
Factor usage does not necessarily equal prescription refill history, and baseline inventories of nonacog alfa were not surveyed. Additionally, the short duration of observation may have led to bias in the ABR. There was no long-term follow-up, so it is unknown how durable the lowering of ABR in adults may be. It should also be noted that no control group was used and It is also important to note the comparison of individual pediatric domain scores obtained in this study with those from Turkish pediatric hemophilia patients in a recently published study by Mercan et al. U.S pediatric patients had substantially lower TSS and, thus, higher QoL scores in physical health, feelings, view, family, and dealing with hemophilia, while scores were similar in the domains of friends, sports/schools, and treatment. The children included in the Mercan et al. Turkish study did not have the benefit of nationally organized HTCs on a scale such as that currently available in the United States, and only about one-half infused at home, which may indicate less ready access to medical care. Educational programs such as BE EMPOWERED specifically emphasize routine and prudent physical activities. The BE EMPOWERED Module 2 stressed reducing bleeding risk with tips for maintaining an active and healthy lifestyle, maintaining a healthy weight, and practicing habits that promote a healthy lifestyle. Child and family awareness of these may have led to high QoL in Family, Others, and Dealing domains as children felt more empowered and encouraged to pursue fulfilling life activities, and families were more at ease with allowing their children such opportunities.
The data reported by Gringeri et al. 14 are more difficult to compare with those of the current report, since the Gringeri et al. study broke TSS out by number of bleeding events in the past 12 months. Using the < 3 ABR as a comparison (ABR in this report was 1), BE EMPOWERED scores were substantially lower, reflecting higher QoL than Gringeri et al.'s report in the dealing domain but substantially higher scores, and
Domain, TSS [SD]
BE EMPOWERED Mercan et al. 13 Gringeri et al. 14 that the study utilized patient self-reported measures. While patient-reported outcomes are often and increasingly utilized in research, it is recognized that a certain level of bias may have been introduced through this method. In addition, at the time of program and study development, the VERITAS (Validated Hemophilia Regimen Treatment Adherence Scale) tool was not yet available. Therefore, the study team developed and utilized a survey that would be appropriate and applicable in a realworld setting for hemophilia B patients. Future work will take into consideration the validation of survey tools developed for this program or will utilize the now available VERITAS tools.
■■ Conclusions
This is the first report that documents the educational impact that a specialty pharmacy can have in the hemophilia B population. The BE EMPOWERED program in adults was associated with a statically significant reduction in the ABR of all bleeds and joint bleeds. The program was also associated with a statistically significant increase in the use of RICE among caregivers of children with hemophilia B. Further work should be performed to extend and expand this pilot program and explore the use of specialty pharmacies in hemophilia B education.
